Part of the ongoing S&P 500 Structural Census study. AbbVie reflects a sustained impulsive structure following the post-2020 expansion phase, with price maintaining higher highs and higher lows. The current phase represents consolidation within the broader uptrend, with no confirmed structural weakness. Structural Status: Sustained Impulsive Structure This analysis is for educational purposes and reflects structural market observation. Structure → Level → Trigger → Probability #SP500Census #MarketStructure #StructuralAnalysis #ABBV #EwavesJournal

Technical Analysis The daily chart shows a descending channel, indicating a correction after a strong rally. Key points: • Strong prior uptrend • Current corrective channel • Price near channel support • Moving average acting as resistance Short-Term Scenarios Bullish Bounce If price holds $200–205 and reclaims $215: Targets: $215 $225 $235 Stop loss $198 Bearish Breakdown If support breaks: Targets: $195 $185 $180 Stop loss $210 Long-Term Outlook AbbVie Inc. still maintains a relatively bullish structure. Targets: $240 $260 $280 Stop loss Below $180 Fundamental Overview AbbVie is a major pharmaceutical company. Pros: • Stable revenue • Strong dividend • Solid pipeline Cons: • Drug dependency risks • Regulatory pressure Final Insight Above $215 → bullish recovery Below $200 → deeper correction

Team, We are not buying now. Price is still trading below major descending resistance (R). As long as we are below R, the structure remains under pressure. ✅ What We Are Waiting For We only buy if: Price breaks above the descending resistance (R) A candle closes clearly above it We see strength (no immediate rejection wick) Ideally: a small pullback that holds above R No breakout = no trade. 🟢 Entry Plan (After Confirmation) Once price: Breaks above R Retests and holds

NYSE:ABBV 28/02/2026 💰 231.02 🟢 Moderate BULL 16.23% at 1.39x 🟢(58.1%):🔴(41.9%) ⏳Clarity:54% Retrace:-0.5% Bounce:3.2% 5.9x 💥 BO+ Bulls are holding the edge here but this is not an aggressive setup. The multi-timeframe count shows 36 green against 24 red across 112 signals, with the higher timeframe trend leaning bullish at 9 green versus 5 red. EMA structure is clean with 13 green and zero red, meaning the trend backbone is intact across all measured timeframes. Ichi TK adds further confirmation at 10 green to 4 red. Where it gets interesting is the breakout classification. The 5.9x reading with BO+ status tells us this move has legs beyond a simple bounce. Price is sitting at the 90th percentile near the upper range between 221.26 and 232.10. Retrace is minimal at just -0.5% which shows buyers are not giving back ground. The cautious part of this read comes from candles. The candlestick count is weak at 3 green versus 11 red, and pattern totals lean bearish at 1 green to 2 red with 2 bearish harami and 2 engulfing reds showing up. This means short-term price action is choppy even though the structural trend is bullish. Spread sits at 20% moderate so there is no extreme extension either way. Volume tells a mixed story. Vol Z is at -0.61 which is quiet, and momentum is decelerating at -1.35. The Bull Bear Z readings are both negative at -0.37 and -0.45 showing neither side is pushing hard on volume. No whale activity detected and no volume squeeze forming. However OBV Z at 2.43 with a strong upward trend is the standout signal here. Accumulation is happening under the surface even though daily volume is not flashy. S.Mom shows expansion declining at 900.6% which means the big move energy is fading but still elevated. No futures data available for this ticker so there is no leverage or derivatives distortion to worry about. This is a clean spot market read. The setup favors longs but patience is key. Clarity at 54% is moderate and the candle weakness suggests pullbacks are possible before continuation. Best approach is to watch for a retrace toward the 221 to 225 zone for a better entry rather than chasing up here near 232 resistance. If OBV continues to climb while price consolidates that would be the ideal reload zone. More analysis on my profile. 🎯 Target: 1K Followers 👉 Follow: stingrayea

AbbVie Inc. (ABBV) has topped on its historic 13-year Channel Up and since its October 2025 All Time High (ATH), which was a Higher High for the pattern, it has been trading sideways at best. This is a strong indication of a potential long-term correction, the likes of which we've been seeing cyclically since its IPO. Since 2022 we've had two -25% corrections on average, both hitting the 1W MA50 (red trend-line) before bottoming and reversing. Before that we've had ABBV's strongest ever correction in 2018-2019 and in 2015 a -36.50% one, both of which touched at lest the 1M MA50 (blue trend-line). As a result, if we see another -24.65% correction in 2026 from the ATH, expect the price to the 195.00 - 185.00 Target Zone. The first will make contact with the 1W MA150 and the last with the 1M MA50. The 1M RSI Support Zone is an additional buy indicator if hit. --- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** --- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇

as we can see abbv is in a bullish channel. we are starting to form a bull flag inside this channel. if we don't break down from this channel, we have a possible target at the top of the channel @275 simple annalist with support and resistant shows us. we have support at 215 if price hits target and doesn't break out of the channel we will have a great buying opportunity with a confluence of support. we have been consolidating sideways for 150 days. we can be in an accumulation zone waiting for a breakout. also, obv indicator is rising during this sideway price range that often confirms accumulation.

After a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now. Current price: ~231 Price is testing the upper boundary of the descending channel. 🔎 Structure Overview • Prior structure: Strong bullish impulse • Current structure: Bearish correction (lower highs + lower lows inside channel) • Moving average flattening → momentum cooling • Price sitting at resistance (channel top) This is a breakout vs continuation decision zone. 🟢 Bullish Scenario (Channel Breakout) If: • Daily close above 235–238 • Strong follow-through candle • Volume expansion Upside targets: • 245 • 255 • Potential continuation toward 265 This would invalidate the corrective channel and signal trend continuation. Long Invalidation: • Rejection from channel top + close below 225 🔴 Bearish Scenario (Correction Continues) If: • Price rejects current resistance • Break below 220 Downside targets: • 210 • 200 (channel base) • Possible overshoot toward 195 This would confirm continuation of corrective structure. Short Invalidation: • Break and hold above 238 📊 Structural Insight Important distinction: • This looks more like a bullish trend in correction, not a full trend reversal yet. • Breakout from descending channel often triggers strong upside expansion. • Failure at resistance increases probability of retest of channel lows.

The chart shows AbbVie Inc. (ABBV) on the daily timeframe. After a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now. Current price: ~231 Price is testing the upper boundary of the descending channel. 🔎 Structure Overview • Prior structure: Strong bullish impulse • Current structure: Bearish correction (lower highs + lower lows inside channel) • Moving average flattening → momentum cooling • Price sitting at resistance (channel top) This is a breakout vs continuation decision zone. 🟢 Bullish Scenario (Channel Breakout) If: • Daily close above 235–238 • Strong follow-through candle • Volume expansion Upside targets: • 245 • 255 • Potential continuation toward 265 This would invalidate the corrective channel and signal trend continuation. Long Invalidation: • Rejection from channel top + close below 225 🔴 Bearish Scenario (Correction Continues) If: • Price rejects current resistance • Break below 220 Downside targets: • 210 • 200 (channel base) • Possible overshoot toward 195 This would confirm continuation of corrective structure. Short Invalidation: • Break and hold above 238 📊 Structural Insight Important distinction: • This looks more like a bullish trend in correction, not a full trend reversal yet. • Breakout from descending channel often triggers strong upside expansion. • Failure at resistance increases probability of retest of channel lows.

ABBV Will Fly Once This Happens NYSE:ABBV is one of those incredible companies, not just because of what they do, but how they do it. They have consistently ranked among the best for employee well-being while successfully bringing to market some of the most patent-protected biotech drugs, such as Humira . Furthermore, they continue to develop even more advanced treatments that are expected to surpass previous sales records. Since 2013, the company has seen steady growth , and there are no signs of that slowing down. While these types of stocks are fantastic, they rarely offer clear entry points that allow you to avoid significant drawdowns. Today, we have an opportunity to enter at the breakout of a bull flag (or channel). This is a clear bullish continuation pattern that aligns perfectly with analyst price targets and the positive progress of their current research and drug pipeline. Breaking above the channel, specifically the $235 mark, would be a strong signal to enter. Given the expected upward momentum, we could use a very tight Stop Loss (SL). I have marked the Fibonacci levels, but this is the kind of stock you could simply hold in a portfolio long-term after a perfect entry. That said, my philosophy is to capture the profit during the rally and then move on to the next opportunity, so I will be focusing on those Fibonacci levels for my exit. On the downside, I would be concerned if we lost $210 , as that could lead us straight to $190 . At that level, I expect to see plenty of buyers, making it an excellent entry point. If that level fails to hold, the bullish trend would likely be over, and it would be best to stay out. Currently, however, it looks like the price is preparing for an imminent upward move. How far ABBV can go? Short-to-Medium Term : If the $235 breakout holds, the immediate Fibonacci extensions often point toward the $255 - $265 range. Long-Term : As long as their new immunology assets (like Skyrizi and Rinvoq) continue to fill the Humira gap, ABBV is positioned as a powerhouse. In a sustained bullish market, seeing it test the $280 - $300 psychological levels over the next 18–24 months is well within the realm of analyst projections. What would be your exit strategy if the price breaks the bull flag? Do you consider a long term hold here? Or a fast profit? 👇 WANT MORE? 🚀 Hit the rocket, read my profile and follow so we can find each other again.

AbbVie is currently trading inside a descending channel, following a strong impulsive bullish move. This structure suggests a controlled correction rather than a trend reversal, at least for now. Price is oscillating around the midline of the channel and near the moving average, indicating short-term balance between buyers and sellers. As long as price remains within the channel, ABBV is technically in a corrective phase. Bullish Scenario • Holding above $205–210 (lower boundary of the channel) • A bounce toward the channel midline or upper boundary • Upside targets: • $225 • $235 • A breakout above the channel would confirm trend continuation. Bearish Scenario • Daily close below $205 • Bearish continuation toward: • $195 • $185 🛑 Stop Loss (English) • Long positions: below $203 • Short positions: above $228 after rejection from resistance